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Inborn errors of metabolism (IEM) are a rare group of genetic diseases which can lead to
several serious long-term complications in newborns. In order to address these issues as
early as possible, a process called tandem mass spectrometry (MS/MS) can be used as it
allows for rapid and simultaneous detection of the diseases. This analysis was performed to
determine whether newborn screening by MS/MS is cost-effective in Thailand.
Method
A cost-utility analysis comprising a decision-tree and Markov model was used to estimate
the cost in Thai baht (THB) and health outcomes in life-years (LYs) and quality-adjusted life
year (QALYs) presented as an incremental cost-effectiveness ratio (ICER). The results
were also adjusted to international dollars (I$) using purchasing power parities (PPP) (1 I$ =
17.79 THB for the year 2013). The comparisons were between 1) an expanded neonatal
screening programme using MS/MS screening for six prioritised diseases: phenylketonuria
(PKU); isovaleric acidemia (IVA); methylmalonic acidemia (MMA); propionic acidemia (PA);
maple syrup urine disease (MSUD); and multiple carboxylase deficiency (MCD); and 2) the
current practice that is existing PKU screening. A comparison of the outcome and cost of
treatment before and after clinical presentations were also analysed to illustrate the poten-
tial benefit of early treatment for affected children. A budget impact analysis was conducted
to illustrate the cost of implementing the programme for 10 years.
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Results
The ICER of neonatal screening using MS/MS amounted to 1,043,331 THB per QALY
gained (58,647 I$ per QALY gained). The potential benefits of early detection compared
with late detection yielded significant results for PKU, IVA, MSUD, and MCD patients. The
budget impact analysis indicated that the implementation cost of the programme was
expected at approximately 2,700 million THB (152 million I$) over 10 years.
Conclusion
At the current ceiling threshold, neonatal screening using MS/MS in the Thai context is not
cost-effective. However, the treatment of patients who were detected early for PKU, IVA,
MSUD, and MCD, are considered favourable. The budget impact analysis suggests that the
implementation of the programme will incur considerable expenses under limited resources.
A long-term epidemiological study on the incidence of IEM in Thailand is strongly recom-
mended to ascertain the magnitude of problem.
Introduction
Inborn errors of metabolism (IEM) comprise more than 30 genetic disorders that can lead to
several serious long-term complications to neonatal and young children [1]. Without rapid
diagnosis and appropriate treatment, these diseases can cause mental retardation (MR), physi-
cal disabilities, and even death [2]. Although the incidence of IEM seems to be low and varied
among different ethnicities [3], high incidences are found in the North American and Euro-
pean populations with an incidence of 40.00 and 29.51 cases per 100,000 live births respectively
[4, 5] whereas the incidences of IEM in Asian populations range between 16.08–26.35 in
100,000 live births [6–8].
Tandem mass spectrometry (MS/MS) is an advanced technology that has the ability to iden-
tify more than 30 diseases [9] by testing compounds from a single dried blood sample collected
from infants during their second to third days of life [10]. Analysis for identifying each condi-
tion is simultaneous and rapid with high specific sensitivity (100%) and specificity (100%) [11].
With this technology, many high- income countries such as Italy, Denmark, Canada, Australia,
Qatar, and Taiwan have expanded their neonatal screening programme in order to cover more
IEM, which in the past consisted of only phenylketonuria (PKU) [12].
In Thailand, a neonatal screening programme was introduced in 1996 to screen for PKU
[13]. Currently, PKU is the only disease screened among the IEM group and the screening
method used is the Guthrie test due to its simplicity and inexpensiveness. For other diseases, to
date, no study has been carried out to identify the magnitude of the problem especially in
terms of incidence and/or prevalence of the diseases in a systematic way. Without such funda-
mental information to support the necessity of advanced and expensive technology, convincing
policy-makers to introduce MS/MS as a population-based screening tool in Thailand will be
very challenging.
So far, many studies have shown that MS/MS is cost-effective in their specific country set-
tings [14–22]. However, due to generalizability and transferability issues, the results of the eco-
nomic evaluations in the original country of study cannot be transferred to other countries
because of the differences in multiple factors (e.g. demography, epidemiology of disease, health
infrastructure, clinical practice, and healthcare cost) [23–25]. Thus, this study was conducted
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to determine the cost-effectiveness of screening and treatment for selected IEM in Thailand.
The result of this study will be mainly used to support policy-makers of the National Health
Security Office (NHSO) to determine whether this screening intervention should be included
into the benefits package of the country’s Universal Health Coverage (UHC) scheme.
Materials and Methods
Selection of IEM disorders
By recognising that screening all diseases detectable by MS/MS may not be possible in Thailand
where healthcare resources are limited. For example, with a small number of physicians who
specialise in IEM treatment, managing medical care for all detected patients is impracticable.
Therefore, only most significant diseases will be screened for an initiative period of the pro-
gramme. Among the diseases detectable by MS/MS, we prioritised which diseases are appropri-
ate to be included in the study. We first held an expert panel of IEM specialists (DW, NV, PW,
VS, SP, and CK) from four major hospitals in Bangkok where most of the IEM patients are
treated to help with the selection of the diseases, including Siriraj Hospital, Ramathibodi Hos-
pital, Chulalongkorn Hospital, and the Queen Sirikit National Institute of Child Health. The
selection criteria were modified from the principle of population-based screening proposed by
the World Health Organization (WHO) based on the recommendations of Wilson and
Jungner [26] which included the magnitude of the health problem, availability of technology
(screening and treatment), safety, and effectiveness of the treatment. As a result, six diseases
consisting of PKU, isovaleric acidemia (IVA), methylmalonic acidemia (MMA), propionic
acidemia (PA), maple syrup urine disease (MSUD), and multiple carboxylase deficiency
(MCD) were selected for an economic evaluation.
Study design
The cost-effectiveness analysis followed the standard guidelines of economic evaluations [27,
28] with present health technology services as the comparator. Thus, the analysis compared: 1)
the current practice—or “pre-expanded newborn screening programme”—where only PKU is
screened using the Guthrie test and PKU patients received early treatment whereas the other
diseases detected were treated after symptomatic presentation; and 2) the “expanded newborn
screening programme using MS/MS” where the six prioritised diseases were screened and
treatment was given early or before symptomatic presentation. The costs and health outcomes
of these alternatives were then compared by taking the societal perspective into account as sug-
gested by Thai Health Technology Assessment guidelines [29].
The health outcomes of interest were measured in life-year gained (LY) and quality-adjusted
life year (QALY) gained. A discount rate of 3% was applied for both the cost and outcome [30].
All costs were subsequently converted to year 2013 adjusted using the consumer price index
medical care for medical goods and services and general consumer price index for those non-
medical and other costs as recommended in the Thai health technology assessment guidelines
[31]. The analyses were performed in Microsoft Excel 2007 (Microsoft Corp., Redmond, WA)
and the results were presented as an incremental cost-effectiveness ratio (ICER) in Thai baht
(THB) per QALY gained. For intercountry comparisons, costs can be converted into interna-
tional dollars (I$) using the purchasing power parity (PPP) exchange rate of 1 I$ = 17.79 THB
(2013) [32]. This analysis used the cost-effectiveness ceiling threshold of one times the gross
domestic product (GDP) per capita (120,000 THB 6,745 I$) per QALY gained as recom-
mended by the Health Economic Working Group under the Subcommittee for Development
of the National List of Essential Drugs and the Subcommittee for Development of the Health
Benefit Package and Service Delivery of the NHSO, Thailand [33].
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Analytical model
A probabilistic multivariate model was conducted using a combination of a decision-tree and
Markov model that followed a cohort of newborns with a cycle-length of one year. Our model
consisted of newborns at birth starting either at the stage of being at risk for one of the six
selected diseases or the normal newborn stage. Next, these newborns were able to transit
through three possible scenarios consisting of early diagnosis, late diagnosis, and normal new-
borns (Fig 1). After that, the affected newborns were followed by applying a Markov model to
capture possible changes in the health status for each year of life within the designated cycle-
length for 100 years or lifetime. This is to ensure that all cost and outcomes related to the dis-
ease and intervention were comprehensively accounted for.
Although the six prioritised IEM diseases have the potential to cause several severe clinical
manifestations, only the most common long-term complications were taken into account as
health states in this analysis (Fig 2). Since it was highly possible that a majority of IEM patients
would have neurological complications, this complication was deemed integral to the model
[1]. The other important long-term complications represented in the model were renal failure
in MMA and cardiomyopathy in PA [34]. Thus, the health states applied in each disease were
divided into three different groups based on the most common long-term complications: 1)
PKU, IVA, MSUD, and MCD (Fig 2A) were designated the health states of living without any
complications, having neurological complications, and death; 2) MMA (Fig 2B) was consisted
of the health states of living without any complications, having neurological complications,
having renal failures, having both neurological and renal complications, and death; and 3) PA
(Fig 2C) was presented the health states of living without any complications, having neurologi-
cal complications, having cardiomyopathy, having both neurological complications and car-
diomyopathy, and death.
Estimation of disease incidences
The incidence of PKU in the Thai population is 2.22 per 100,000 live births. This data was
obtained through a newborn screening programme at Siriraj Hospital—which had screened
over 180,000 infants born in Bangkok Metropolitan—as well as a continuity programme for
screening-positive cases [35]. Due to the lack of existing data on the incidences of the other
IEM in Thai setting, the present study adopted the incidences of other Asian populations—spe-
cifically the Chinese and Japanese—which were considered comparable to Thai ethnicity. The
incidence of the remaining five IEM ranged from 0.54 to 2.69 cases per 100,000 live births [7]
[8] (Table 1).
Transitional probabilities of long-term complications and mortality
Transitional probabilities, or tp(u) (i.e., transition to long-term complications and/or death),
are required for the Markov model to simulate the events of patients entering each health state
(Table 1). Our base-case analysis mainly estimated a baseline rate of long-term complications
using a retrospective review of the registered medical records of patients with the six IEM dis-
eases at the four hospitals from 1992 to 2012. The data consisted of clinical variables such as
the survival time, demographics, clinical complications, and patient status (alive/dead) of 119
patients (IVA = 23, MMA = 20, PA = 8, PKU = 26, MSUD = 32, and MCD = 10). The annual
transitional probabilities of long-term complications were estimated by employing nonpara-
metric methods and the annual probabilities of mortality were estimated using survival
analysis.
A parametric survival-time model was applied in order to derive a time-dependent proba-
bility of mortality for IVA, MMA, PA, and MSUD. In particular, a Weibull model which was
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compared with exponential model was used as the AIC (Akaike information criterion) indi-
cated that it was more fit to the actual data. The survival function, S(t) which describes the
Fig 1. Simplified-decision-tree. Comparing the strategies of expanding the newborn screening programme with the pre-expanded newborn screening
programme. MS/MS = Tandemmass spectrometry; PKU = phenylketonuria; M = Markov model.
doi:10.1371/journal.pone.0134782.g001
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probability of survival as a function of time is [48]:
SðtÞ ¼ expfHðtÞg ð1Þ
and
HðtÞ ¼ ltg ð2Þ
whereH(t) which is the cumulative hazard; λ (lambda) is the scale parameter; t is time in years;
and and ancillary or γ (gamma) is the shape parameter that describes the instantaneous death
rate, the hazard rate h(t), which increase which time if γ> 1.
The transitional probability of dying during the cycle, tp(u), is therefore estimated from the
following formula (where u is the cycle-length of the model):
tpðuÞ ¼ 1 expflðt  uÞg  ltgg ð3Þ
For PKU and MCD, the reviewed data showed that patients who were admitted to hospitals
were all still alive which prevented us from capturing their lifespan by applying survival analy-
sis. In the case of PKU, the probability was adopted from the data of the United States’ national
survey on PKU[36] whereas the lack of long-term literature on MCD patients required the
experts to make the assumption that their mortality is equivalent to the normal population. In
addition, for all six IEM, apart from the probability of mortality caused specifically by the dis-
eases, the model also included death from other causes estimated from the Thai life table [49]
(S1 Table).
Sensitivity and specificity
At present, only PKU is screened using the Guthrie test. This traditional method yielded a sen-
sitivity of 98.50% and specificity of 99.50% [39] as shown in Table 1.
Due to a prior systematic review supporting the high accuracy of MS/MS [19], we assumed
a screening test sensitivity of 100% and specificity of 100% (Table 1). The expert panel also
Fig 2. Markovmodel.Health states transition of selected IEM. (A) represents PKU, IVA, MSUD and MCD; (B) represents MMA; and (C) represents PA.
PKU = phenylketonuria; IVA = isovaleric acidemia; MMA =methylmalonic acidemia; PA = propionic acidemia; MSUD =maple syrup urine disease;
MCD =multiple carboxylase deficiency.
doi:10.1371/journal.pone.0134782.g002
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Table 1. Mean and standard error (SE) of transitional probabilities used in the model.
Parameter Distribution Mean SE Reference
Uptake rate Beta 0.97 0.0001 [38]
MS/MS sensitivity Beta 1.00 - [19]
MS/MS specificity Beta 1.00 - [19]
Guthrie sensitivity Beta 0.9850 0.01 [39]
Guthrie specificity Beta 0.9995 0.01 [39]
Incidence of diseases
PKU Beta 2.22ˣ10−5 1.11ˣ10−5 [35]
IVA Beta 1.08ˣ10−5 5.38ˣ10−6 [8]
MMA Beta 2.69ˣ10−5 8.50ˣ10−6 [8]
PA Beta 5.40ˣ10−6 3.80ˣ10−6 [8]
MSUD Beta 1.08ˣ10−5 5.38ˣ10−6 [8]
MCD Beta 6.60ˣ10−6 3.30ˣ10−6 [7]
Death from the diseasea
Yearly probability
PKU Age 0 to < 10 years Beta 2.53ˣ10−3 - Estimated from [36]
Age 10 to < 20 years Beta 2.88ˣ10−2 -
Age 20 to < 30 years Beta 4.57ˣ10−3 -
Age 30 to < 40 years Beta 4.39ˣ10−3 -
Age 40 to < 50 years Beta 3.54ˣ10−3 -
Age 50 to < 60 years Beta 3.24ˣ10–3 -
Age  60 Beta 1.13ˣ10–1 -
Survival analysis
IVA Constant for baseline hazard Lognormal -2.515 0.721 Medical record review
Ancillary parameter in Weibull distribution Lognormal -1.424 0.371 Medical record review
MMA Constant for baseline hazard Lognormal -4.070 1.690 Medical record review
Ancillary parameter in Weibull distribution Lognormal -0.865 0.532 Medical record review
PA Constant for baseline hazard Lognormal -3.970 1.662 Medical record review
Ancillary parameter in Weibull distribution Lognormal -0.745 0.477 Medical record review
MSUD Constant for baseline hazard Lognormal -4.790 1.123 Medical record review
Ancillary parameter in Weibull distribution Lognormal -0.665 0.289 Medical record review
Long-term complications (Yearly probability)
PKU Neurological complication Beta 0.1340 0.0852 [37]
IVA Neurological complication Beta 0.0509 0.0549 Medical record review
MMA Neurological complication Beta 0.0897 0.0730 Medical record review
Renal failure Beta 0.0339 0.0487 Medical record review
PA Neurological complication Beta 0.6838 0.2080 Medical record review
Cardiomyopathy Beta 0.0468 0.1056 Medical record review
MSUD Neurological complication (Age 0 to <1 year) Beta 0.2778 0.1056 Medical record review
Neurological complication (Age 1 to < 2 years) Beta 0.3846 0.1147 Medical record review
Neurological complication (Age = >2) Beta 0.6250 0.1122 Medical record review
MCD Neurological complication (Age 0 to < 3 years) Beta 0.0572 0.0774 Medical record review
Neurological complication (Age 3 to < 7 years) Beta 0.0646 0.0819 Medical record review
Neurological complication (Age = > 7 years) Beta 0.0218 0.0487 Medical record review
Relative risk of early compared with clinical diagnosis
PKU Mortality Beta 0.67 - [36]
Neurological complication (RR) Lognormal 0.02 0.03 [37, 40, 41]
IVA Mortality reduction Beta 0.20 - [42]
(Continued)
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agreed with this assumption that a sensitivity and specificity of 100% for both should be used.
As such, this meant that no IEM cases were missed by the MS/MS screening programme.
Outcome of early detection
A relative risk (RR) was used as the main outcome measure. The RR of the experimental or
screened group compared with the clinical diagnosed group on neurological complications or
other complications of each IEM disease—was obtained based on a systematic search through
Ovid MEDLINE and Embase. Detailed information about the systematic search is available in
(S1 Search Strategy). Where data was available, pooling RR was performed (Table 1). The effec-
tiveness in the reduction of neurological complication of patients with early detection of PKU
was calculated based on data from three cohort studies consisting of: a collaborative study of
children treated for PKU in the US [41]; a study in Italy from the Regional Center for Inborn
Errors of Metabolism [40]; and a retrospective study of PKU patients diagnosed and controlled
in Spain [37] (RR 0.02, 95%CI (0.00–0.09)). For IVA patients, the reduction in risk of neuro-
logical complications was estimated based on a literature review investigating 155 IVA patients
worldwide (RR 0.28, 95%CI (0.07–0.50)) [43]. Two case series reports of MSUD patients diag-
nosed in the US [46] and Japan [45] were pooled to estimate the reduction of neurological
complications (RR 0.23, 95%CI (0.01–0.45)). For MMA and PA patients, the review study of
cases around the world comparing symptomatic cases and those diagnosed through newborn
screening [34] was used to calculate the RR of neurological complications (RR 0.63, 95%CI
(0.00–1.00) for MMA, and RR 0.73, 95%CI (0.00–1.00) for PA) as well as the RR of renal failure
in MMA patients (RR 0.33, 95%CI (0.00–0.93)). The RR of cardiomyopathy in PA patients was
0.46 (95%CI (0.00–1.00)) based on a German study comparing PA patients diagnosed through
newborn screening and those obtained through clinical diagnosis [44]. In the case of MCD, we
assumed no long-term complications if early detection and treatment was provided as results
according to the report of American Academy of Paediatrics [47] and previously published
data [14] showed.
Table 1. (Continued)
Parameter Distribution Mean SE Reference
Neurological complication (RR) Lognormal 0.28 0.11 [43]
MMA Mortality reduction Beta 0.25 - [42]
Neurological complication (RR) Lognormal 0.63 0.41 [34]
Renal failure (RR) Lognormal 0.33 0.31 [34]
PA Mortality reduction Beta 0.25 - [42]
Neurological complication (RR) Lognormal 0.73 0.30 [34]
Cardiomyopathy (RR) Lognormal 0.46 0.95 [44]
MSUD Mortality reduction Beta 0.20 - [42]
Neurological complication (RR) Lognormal 0.23 0.11 [45, 46]
MCD Mortality reduction Beta 1.00 - [47]
Neurological complication (RR) Lognormal 0.00 - [14, 47]
a See S1 Table for death from other causes.
PKU = phenylketonuria; IVA = isovaleric acidemia; MMA = methylmalonic acidemia; PA = propionic acidemia; MSUD = maple syrup urine disease;
MCD = multiple carboxylase deficiency; RR = Relative risk of early-diagnosed patients compared with clinical diagnosed patients
doi:10.1371/journal.pone.0134782.t001
An Economic Evaluation of Neonatal Screening in Thailand
PLOS ONE | DOI:10.1371/journal.pone.0134782 August 10, 2015 8 / 25
An extensive search of literature was also conducted to determine the benefit of early detec-
tion for reduction of mortality in patients but no any robust evidence-based information was
found. Nevertheless, the potential data found could be an estimation of UK paediatrician on
reduction on death of early-diagnosed IVA, MMA, PA, and MSUD patients ranged between
20%-25% given to a previous study [42]. So, the information was adopted into the model. For
PKU and MCD patients, normal life expectancy was assumed for the effectiveness of early
detection which was supported by the data from medical record reviews which showing no
PKU and MCD patients died due to the disease (Table 1).
Screening costs
Two sample quotations of MS/MS manufacturers and distributors were obtained to estimate
the capital and material costs of the MS/MS screening programme. In terms of human
resources, a proportion of labour costs to capital and material costs from international publica-
tions [15, 16, 19] were estimated and applied to the analysis (Table 2).
To screen around 750,000 births per year, we estimated that Thailand requires 7 to 9 MS/
MS machines. When requesting for the sample quotations, we received a difference in terms of
price. The cost per MS/MS machine ranged from 9.8 to 15 million THB in addition to an
annual maintenance fee of 1.8 to 4.8 million THB. To calculate for depreciation, the equipment
would have a lifetime of 7–8 years life without the salvage value. The prices of reagent per sam-
ple were also considerably dissimilar at 111 and 300 THB per sample. Meanwhile, the labour
cost accounted for approximately 28% of the screening cost and was calculated to be 64 THB
per sample. Thus, from this information, the cost of MS/MS screening per sample was esti-
mated to be 294 THB per sample (Table 2).
Treatment costs
This study was approached from a societal perspective so all costs relevant to patient, health
care system, and society were analysed. A cost analysis was conducted specifically for each of
the six prioritised diseases. Treatment costs mainly included hospitalisation expenses and die-
tary management. Retrospective information of the treatment costs for the IEM patients was
collected from each of the four hospitals’ databases, and then the resulting data were pooled
and analysed together (Table 2).
From the data, it was evident that the cost of inpatient care (IPD) was very high in the first
year of treatment due to an acute phase. The treatment cost decreased dramatically in the sec-
ond year of treatment. Thus, the IPD cost was divided into two periods: 1) the first year of
treatment; and 2) the second year of treatment onwards. Regarding the cost of outpatient care
(OPD), the cost per year was estimated by multiplying the cost per visit by the number of out-
patient visits per year (S2 Table).
Additionally, the cost of the supplemental metabolic formula was calculated based on the
assumption that patients needed a special formula for their lifespan to maintain normal meta-
bolic function. Price of this special product was provided by manufacturer and the data of
quantity used for patients was obtained from the IEM specialists. Regarding the cost of other
supplemental products such as orphan drugs, vitamins, and cofactors, the IEM specialists were
asked to answer a set of questions on a provided questionnaire survey about the type, the quan-
tity, and the unit price of the product being used to treat their IEM patients. For productivity
loss and direct-non medical costs, data were collected via face-to-face interviews with the
patients’ families using a structured questionnaire. The parents of the IEM patients were asked
about the time spent to look after their children who have been disabled due to complications
caused by IEM. The average wage in Thailand [50]—classified by gender and age—was used
An Economic Evaluation of Neonatal Screening in Thailand
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Table 2. Means and standard error (SE) of cost parameters presented in 2013 Thai Baht. 1 I$ = 17.79 THB.
Parameter Distribution Mean SE Reference
Screening cost for MS/MS (per sample) Gamma 294 126 Survey
Screening cost for Guthrie (per sample) Gamma 5.00 - NSCO
Confirmation cost (per sample) Gamma 2,349 168 Hospital database
Hospital inpatient care (IPD) cost per year
First year of treatment
PKU Gamma 80,316 19,899 Hospital database
IVA Gamma 174,006 53,349 Hospital database
MMA Gamma 252,457 81,466 Hospital database
PA Gamma 284,718 91,965 Hospital database
MSUD Gamma 252,859 53,281 Hospital database
MCD Gamma 92,070 25,721 Hospital database
Second year of treatment onward
IVA Gamma 21,290 3,712 Hospital database
MMA Gamma 191,729 73,046 Hospital database
PA Gamma 160,951 44,432 Hospital database
MSUD Gamma 52,580 15,029 Hospital database
MCD Gamma 69,615 60,111 Hospital database
Hospital outpatient care (OPD) cost per year
PKU Gamma 16,366 321 Hospital database
IVA Gamma 44,925 1,335 Hospital database
MMA Gamma 108,671 2,272 Hospital database
PA Gamma 61,328 2,142 Hospital database
MSUD Gamma 17.928 519 Hospital database
MCD Gamma 4,055 362 Hospital database
Pharmaceutical product per yeara
L-carnitine (IVA, MMA) Gamma 1,470 - Survey
L-glycine (IVA) Gamma 276 - Survey
Cobalamin (MMA, PA) Gamma 7,350 - Survey
Biotin (PA) Gamma 13,597 - Survey
Biotin for (MCD) Gamma 10,198 - Survey
Metabolic formula per year
PKU Age 0 to < 4 years Gamma 75,511–81,552 - Survey
Age 4 years Gamma 45,306 - Survey
IVA Age 0 to < 5 years Gamma 51,347–78531 - Survey
Age 5 years Gamma 45,306 Survey
MMA Age 0 to < 7 years Gamma 51,347–75,511 - Survey
Age 7 years Gamma 45,306 Survey
PA Age 0 to < 7 years Gamma 51,347–75,511 - Survey
Age 7 years Gamma 45,306 Survey
MSUD Age 0 to < 4 years Gamma 55,878–86,082 - Survey
Age 4 years Gamma 45,306 Survey
Direct non-medical cost per year
PKU with long-term complications Gamma 27,704 - Survey
without long-term complications Gamma 12,941 9,768 Survey
IVA with long-term complications Gamma 27,704 - Survey
without long-term complications Gamma 15,781 4,924 Survey
MMA with long-term complications Gamma 46,516 20,107 Survey
(Continued)
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for calculating the productivity loss or opportunity cost. We also inquired about costs relevant
to hospitalisation such as travel costs from home to the hospital. From the data obtained, the
differences between the cost of mild and severe cases were observed, and the costs for these
cases were therefore classified into two groups according to the severity/complication of the
disorder(s), including without complications and with complications (Table 2).
Utility measurement
There are several concerns about assessing health utility weight from children, especially an
available and appropriate measuring instrument allowing children to complete their health sta-
tus [51]. In addition, both small number of living patients and their intellectual disabilities sta-
tus are factors that make it possibly impossible to perform primary data collection. Therefore,
the estimation of health utility was conducted by holding an expert panel consisting of the six
IEM specialists as proxies.
EuroQoL Five-Dimension Questionnaire (EQ-5D) was applied as a tool to estimate health
utility weight of each health stage of each disease. The IEM specialists were then asked to recall
from their current as well as previous IEM patients. Then, they filled out a score onto the pre-
pared paper sheet. Subsequently, the average score was presented and discussed among the
experts. As a result, a consensus for health utility weight was reached and applied into the
model (Table 3).
Table 2. (Continued)
Parameter Distribution Mean SE Reference
without long-term complications Gamma 22,408 15,429 Survey
PA with long-term complications Gamma 36,348 26,618 Survey
without long-term complications Gamma 22,408 15,429 Survey
MSUD with long-term complications Gamma 45,770 22,843 Survey
without long-term complications Gamma 22,408 15,429 Survey
MCD with long-term complications Gamma 27,704 - Survey
without long-term complications Gamma 14,361 7,346 Survey
Productivity cost per year
PKU with long-term complications Gamma 26,522 2,235 Survey
without long-term complications Gamma 127,896 - Survey
IVA with long-term complications Gamma 129,930 - Survey
without long-term complications Gamma 43,944 5,469 Survey
MMA with long-term complications Gamma 177,404 20,107 Survey
without long-term complications Gamma 50,880 11,493 Survey
PA with long-term complications Gamma 128,784 11,010 Survey
without long-term complications Gamma 50,880 11,493 Survey
MSUD with long-term complications Gamma 105,717 9,573 Survey
without long-term complications Gamma 50,880 11,493 Survey
MCD with long-term complications Gamma 129,930 - Survey
without long-term complications Gamma 35,444 85,000 Survey
aCalculated at patient weight 1 kilogram.
NSCO = Neonatal Screening Operation Centre; PKU = phenylketonuria; IVA = isovaleric acidemia; MMA = methylmalonic acidemia; PA = propionic
acidemia; MSUD = maple syrup urine disease; MCD = multiple carboxylase deficiency
doi:10.1371/journal.pone.0134782.t002
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Uncertainty analysis
To investigate the robustness of the cost-effectiveness results, we performed two types of uncer-
tainty analysis. The first was a one-way sensitivity analysis which examined the effect of
changes in key parameters on the ICERs of the base-case scenario. These variables included:
the incidence of six selected IEM; probability of long-term complications; the effectiveness of
the screening intervention (RR); health utility weight of six selected IEM; first year IPD and
OPD costs; second year direct medical costs; metabolic formula and pharmaceutical product
costs; direct non-medical cost of patients with complication; direct non-medical cost of
patients without complication; productivity loss of patients with complication; productivity
loss of patients without complication; uptake rate of screening; and MS/MS screening cost.
Since each of these variables (except for the uptake rate and the screening cost) comprised six
different values which varied by disease, we assumed that these values simultaneously changed
in the same direction to the lower or upper bound once each variable was examined. The value
being tested varied based on a 95% confidence interval (CI) of these parameters with standard
errors. The costs of the metabolic formula and pharmaceutical products—which are parame-
ters without standard error—were assumed to be varied by 50% from their mean value. Other
parameters (not one being tested) were randomly generated by using a probabilistic sensitivity
method.
The second, a probabilistic sensitivity analysis (PSA), was also conducted to assess the
uncertainty involving all model parameters according to their mean, standard error (SE), and
distribution shown in Tables 1 to 3. Probability distributions were defined as follows: (1) beta-
distributions were assigned where parameter values ranged from zero to one, such as transition
probabilities and utility parameters; (2) gamma-distributions were specified when parameter
values were above zero and positively skewed by costs variables; and (3) a log-normal distribu-
tion was used for survival parameters and RR. A Monte Carlo simulation performed in Micro-
soft Excel 2007 (Microsoft Corp., Redmond, WA) was employed to generate 1,000 rounds of
the simulation to demonstrate a range of plausible lifetime costs, health outcomes (LYs and
QALYs), and ICERs. The result of the analysis was plotted in a cost-effectiveness plane. More-
over, the result was further analysed for a relationship between the values of the ceiling ratio
and the likelihood of favouring each screening strategy as the result is illustrated using cost-
effectiveness acceptability curves showing.
Budget impact analysis
Based on the model, a budget impact analysis (BIA) was also conducted by following the stan-
dard BIA frameworks for healthcare intervention in Thailand [52] along with international
protocol [53]. The analysis applied the perspective of the budget holder in Thailand, i.e. the
NHSO, and aimed to project the financial plans between the implementation of the new
screening programme and the status quo. The costs were analysed and reported into two cate-
gories: screening cost and treatment cost. The costs were inflated at 0.5% each year [31] with a
time horizon of 10 years. Since there is a stable trend for population growth in Thailand, the
annual cohort of newborns was fixed at 750,000 per year [54]. The analysis was based on the
important assumption that the new programme will be managed by the existing screening
organization, i.e. the neonatal screening operation centre, and will replace the current PKU
screening. Therefore, there is no cost of setting up a new department in order to handle the
programme. The machine cost was considered as a fixed capital cost and was spread out
equally throughout each year of the programme based on the concept of equivalent annual cost
[55], while reagent and administrative costs were variable costs dependent on the number of
participants. We conservatively assumed that the uptake for the new screening programme was
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80% for the first year of the implementation and then increased it to 85%, 90%, 95%, and 100%
in subsequent years. The minimum cost and maximum cost scenarios of the screening budget
was examined based on the range of 95% CI of screening costs, while the scenario of the treat-
ment budget was tested based on the incidence of disease (varying the incidence of all diseases
simultaneously to the lower and upper bounds).
Results
Cost-effectiveness analysis of the pre-expanded and the expanded
newborn screening programme
The cost-effectiveness analysis via the adoption of a new screening strategy compared with the
existing screening programme indicate ICERs of 602,606 THB per LY gained (33,873 I$ per LY
gained) and 1,043,331 THB per QALY gained (58,647 I$ per QALY gained) (Table 4), both of
which are above the agreed threshold currently used in Thailand.
In order to understand the potential benefit of screening at the individual diseases level,
Table 5 illustrates the lifetime outcome of each affected child once they are detected early or
Table 3. Health utility weight of IEM patients.
Utility estimated Distribution Mean SE Reference
PKU without long-term complication Beta 0.71 0.02 Expert panel
with mental retardation Beta 0.13 0.19 Expert panel
IVA without long-term complication Beta 0.71 0.07 Expert panel
with mental retardation Beta 0.00 0.15 Expert panel
MMA without long-term complication Beta 0.62 0.06 Expert panel
with mental retardation Beta 0.16 0.18 Expert panel
with renal failure Beta 0.45 0.16 Expert panel
with mental retardation and renal complication Beta 0.14 0.22 Expert panel
PA without long-term complication Beta 0.49 0.13 Expert panel
with mental retardation Beta 0.05 0.21 Expert panel
with cardiomyopathy Beta 0.41 0.20 Expert panel
with mental retardation and cardiomyopathy Beta 0.00 0.28 Expert panel
MSUD without long-term complication Beta 0.60 0.07 Expert panel
with mental retardation Beta 0.00 0.04 Expert panel
MCD without long-term complication Beta 0.84 0.11 Expert panel
with mental retardation Beta 0.51 0.07 Expert panel
PKU = phenylketonuria; IVA = isovaleric acidemia; MMA = methylmalonic acidemia; PA = propionic acidemia; MSUD = maple syrup urine disease;
MCD = multiple carboxylase deficiency
doi:10.1371/journal.pone.0134782.t003
Table 4. Costs, health outcomes, and incremental cost-effectiveness ratios (ICERs) of two neonatal screening programmes. 1 I$ = 17.79 THB.















153.27 — 66.42256 — — 66.42229 — —
Expanded newborn
screening programme
676.55 523.28 66.42343 0.00087 602,606 66.42279 0.00050 1,043,331
doi:10.1371/journal.pone.0134782.t004
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late. The analysis suggests that early medical treatment substantially improves the health out-
come in PKU patients resulting in 9.60 QALY higher than those with late detection. IVA
patients also noticeably benefit from early detection which extends their QALY by 3.69. In
MSUD patients, early detection also yields better health outcomes that help prolong QALY by
2.73. In terms of lifetime costs, the difference between providing early healthcare and late
healthcare to those with MSUD, IVA, and PKU ranges between 200,045 THB (11,245 I$) and
502,913 THB (28,269 I$) per patient. MCD patients gain 1.66 QALY from early detection and
it is the only disease where early medical management reduces the patient’s lifetime costs
(-256,779 THB (-14,434 I$)). However, in most diseases, the costs of giving lifetime care in
patients detected early are higher than those in clinically diagnosed patients; it is clear that
being detected early requires significantly much more costs in MMA and PA patients
(1,783,826 THB (100,271 I$) and 1,241,945 THB (69,811 I$), respectively), which is obviously
high relative to their health outcome gained (2.83 QALY and 0.81 QALY for MMA and PA,
respectively).
Uncertainty analysis
The results of the one-way sensitivity analysis using probabilistic model was further elaborated
upon using a tornado diagram as shown in Fig 3, indicating that the most sensitive factor to
ICER (THB per QALY gained) was the incidence. This was followed by: the MS/MS screening
cost; RR reduction; and health utility. Among the factors least sensitive to the results were the
uptake rate, productivity loss, and direct non-medical costs.
Fig 4 shows the result of the probabilistic sensitivity analysis. Monte Carlo simulation indi-
cated that compared to the ‘current practice’ strategy, the ‘expanded newborn screening’ strat-
egy was more costly but more effective in more than 95% of the simulated cases. The average
patient with screening accrued 0.00048 (95% CI: 0.00023–0.00077), and THB 484.09 (95% CI:
218.25–839.59) more QALYs and costs than that without screening, giving an ICER of THB
1,060,240 (95% CI: 534,228–2,195,143) per QALY which, however, exceeds the threshold for
cost-effective intervention in Thailand (THB 120,000 per QALY).
Fig 5 illustrates the cost-effectiveness acceptability curves representing the probability of
both screening programme scenarios at different thresholds or willingness to pay being cost-
effectiveness. When considering willingness to pay at less than Thailand’s value of one times
the 2013 GDP per capita per QALY gained, the current screening programme has the potential
to be more cost-effective. However, if the threshold is higher than approximately 1,100,000
THB per QALY gained, the MS/MS screening programme becomes a better option.
Budget impact analysis
From Table 6, it can be expected that the screening programme will have a total cost of 191.9
million THB per year in the earlier period and continually increase to above 300 million THB
after seven years of implementation. In detail, the cost of screening is estimated to be 179.8 mil-
lion THB in the first year and stays roughly at 200 million THB after three years of operation.
Whereas the treatment cost is only a small proportion compared to the total cost in the earlier
years (e.g. 12.1 million THB in 2013), it subsequently grows rapidly and is estimated to reach
93.9 million THB in the tenth year; this amount accounts for nearly one-third of the total cost
in that year. It is obvious that the total expense of the screening programme is expected to
increase overtime and the costs of treatment will be more and more substantial for the overall
budget as illustrated in Fig 6. The analysis also found that there is a considerable switching cost
from the current practice to the new programme, amounting to 2,539.6 million THB for the
ten-year period.
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Discussion
Based on the current threshold recommended in Thailand, the results of the present study sug-
gest that implementing the MS/MS screening programme does not meet the criteria for cost-
effectiveness. The incidence rate and the MS/MS screening cost are some of the major parame-
ters influencing the cost-utility results followed by the RR reduction and health utility weight.
A one-way sensitivity analysis shows that changing the parameters’ values did not affect the
conclusion of the study. The result of the probabilistic analysis suggests that the better option is
to continue implementing the Guthrie test for PKU. However, the benefits of early manage-
ment for IVA, MSUD, PKU, and MCD patients are attractive. The budget impact analysis sug-
gests that the likely costs of implementing the programme is about 2,700 million THB over a
projection of 10 years.
Table 5. Difference of lifetime health outcomes and costs per patient after early detection or late detection. 1 I$ = 17.79 THB. The result was under
adjusting of 3.0% discounting rate. Undiscounted version was provided as (S3 Table). PKU = phenylketonuria; IVA = isovaleric acidemia;
MMA =methylmalonic acidemia; PA = propionic acidemia; MSUD =maple syrup urine disease; MCD =multiple carboxylase deficiency; RR = Relative risk of
early-diagnosed patients compared with clinical diagnosed patients.














PKU 3,145,203 2,642,290 502,913 29.55 19.57 9.99 20.91 11.31 9.60
IVA 3,728,014 3,409,629 318,384 17.63 14.84 2.79 11.51 7.82 3.69
MMA 7,685,602 5,901,776 1,783,826 16.33 12.14 4.19 8.67 5.84 2.83
PA 3,838,684 2,596,739 1,241,945 8.82 5.70 3.12 1.25 0.74 0.81
MSUD 3,462,620 3,262,575 200,045 14.88 12.64 2.24 3.93 1.20 2.73
MCD 2,544,647 2,801,427 -256,779 29.59 28.77 0.81 24.75 23.09 1.66
doi:10.1371/journal.pone.0134782.t005
Fig 3. One-way sensitivity analysis. Tornado graph showing results of one-way sensitivity analysis derived from probabilistic method. These figures
indicating parameters which have the largest effect on incremental cost effectiveness ratio or ICER (THB per QALY gained) when they are varied individually.
IPD = cost of inpatient care; OPD = cost of outpatient care.
doi:10.1371/journal.pone.0134782.g003
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To our knowledge, this is the first study that comprehensively evaluated the cost-effective-
ness of MS/MS in low- and middle-income countries (LMICs). All previous economic evalua-
tions of MS/MS were conducted in high-income countries. Of those evaluations, most of
studies represented cost-utility analyses [14, 16, 17, 20, 22, 56] followed by cost-effectiveness
analyses [15, 18, 19, 42, 57]. Most studies also adopted a societal perspective [14, 15, 19, 56] or
used a health care provider’s perspective [17, 19, 20, 42], while a few applied the purchaser
view [16, 22]. The most frequently used comparator in the studies is the no screening pro-
gramme [14, 16–18, 20], followed by offering only PKU using the Guthrie test [15, 19, 42]. The
result found in this study is not comparable with studies in other settings where most of the
studies concluded that the screening programme is cost-effective either in screening for a com-
bination diseases like in the US (California [16, 20], Wisconsin [17], Texas [22]), Australia
[18], and UK [42] or screening for only some preferred disease like in UK [19] Canada [15]. As
such, there are several differences between our study and the previous studies which need to be
addressed.
Firstly, one important factor highly sensitive to the cost-effectiveness results of the screening
programme is the incidence of diseases [14, 17]. A high burden in some particular diseases
tends to make the intervention favourable, especially for diseases with effective outcomes of
treatment such as PKU and medium-chain acyl-coenzyme A dehydrogenase deficiency
Fig 4. Cost-effectiveness plane.Monte Carlo simulation results on cost-effectiveness plane for the expanded newborn screening showing interval
estimates for cost, outcome and incremental cost-effectiveness ratio. The figure shows the horizontal I-bar representing the 95% uncertainty interval on life-
year gained, the vertical I-bar representing the 95% uncertainty interval on incremental cost, and the wedge represent the 95% uncertainty interval on the
ICER. THB = Thai baht; ICER = incremental cost effectiveness ratio.
doi:10.1371/journal.pone.0134782.g004
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Fig 5. Acceptability curve. The graph shows the probabilities of each strategy being cost-effective at a given ceiling ratio. The dashed lines represent the
willingness to pay thresholds for the adoption of health interventions in Thailand.
doi:10.1371/journal.pone.0134782.g005
Table 6. Estimated annual budget impact during 2013 to 2022 of the MS/MS screening programme implementation compared with the status quo
(million THB). 1 I$ = 17.79 THB
Yeara Expanded newborn screening programme Status quo Difference















2013 179.8 102.8 256.8 12.1 8.5 15.8 191.9 3.6 3.6 3.6 3.2 2.8 3.6 6.8 185.0
2014 190.8 109.4 272.3 20.5 14.4 26.7 211.3 3.6 3.6 3.6 5.2 4.4 6.0 8.8 202.5
2015 202.0 116.1 287.9 29.4 20.6 38.3 231.4 3.7 3.7 3.7 7.1 5.9 8.2 10.7 220.7
2016 213.2 122.9 303.6 39.2 27.5 51.0 252.5 3.7 3.7 3.7 6.9 7.4 10.5 10.6 241.9
2017 224.6 129.8 319.4 49.6 34.7 64.4 274.1 3.7 3.7 3.7 10.3 8.5 12.1 14.0 260.1
2018 225.6 130.8 320.4 58.8 41.2 76.5 284.4 3.7 3.7 3.7 11.7 9.7 13.8 15.5 269.0
2019 226.7 131.9 321.5 67.7 47.4 88.1 294.4 3.7 3.7 3.7 13.1 10.8 15.4 16.9 277.5
2020 227.7 132.9 322.5 76.5 53.6 99.5 304.2 3.8 3.8 3.8 14.5 11.9 17.1 18.3 286.0
2021 228.8 134.0 323.6 85.2 59.7 110.7 314.0 3.8 3.8 3.8 15.9 13.0 18.7 19.7 294.3
2022 229.8 135.0 324.6 93.9 65.7 122.0 323.7 3.8 3.8 3.8 17.2 14.2 20.3 21.0 302.6
Total 2148.9 1245.6 3052.3 533.0 373.3 692.8 2681.9 37.1 37.1 37.1 105.2 88.6 125.9 142.4 2539.6
a The uptake rate was assumed at 80%, 85%, 90%, 95%, and 100% in 2013, 2014, 2015, 2016, and 2017–2022, respectively.
Min = minimum; Max = maximum
doi:10.1371/journal.pone.0134782.t006
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(MCAD) [17, 19]; all previous studies were conducted in countries with a high incidence of
PKU. For example, in the UK, the incidence of PKU used in that study was 9.00 cases per
100,000 live births while the incidence of MCAD claimed in the UK and American studies
were 8.00 and 4.50 per 100,000 live births [17, 19], respectively. In contrast, the incidence of
PKU adopted in our study was 2.22 in 100,000 live births or about four times lower than the
UK incidence. Furthermore, MCAD was not included due to it being uncommon in Thai and
Asian population [58]. In relation to this point, a systematic literature review of the economic
evaluation of an MS/MS screening programme also mentioned that the dissimilarity in the
demography of the countries and regions led to different MS/MS cost-effectiveness results
[57].
Secondly, the cost of treatment is another key variable influencing the difference in findings.
Ideally, an early diagnosis will prevent patients from serious clinical consequences resulting in
less health resources required for treatment. If this is the case, it will lead to a programme that
is more economically favourable. For example, in US, Schoen et al 2002 [20] indicated that if
glutaric aciduria type I (GA1) patients were diagnosed early, the cost of treatment will be
decreased about 46% compared with patients who were diagnosed late. The same amount of
reduction was applied with other diseases such as MMA and PA [20]. In contrast, based on the
treatment costs analysed from the hospitals, we did not find a difference between the costs of
patients diagnosed early or late. This could be because even though early detection can prevent
patients from severe clinical consequences at an acute period and help avoid some unnecessary
Fig 6. Budget Trend. The trend of the budget required for the screening programme compared with the current situation over ten years. THB = Thai baht.
doi:10.1371/journal.pone.0134782.g006
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costs for treatment, patients will still need more for preventive treatment in order to maintain
their health. Therefore, patients diagnosed earlier can live longer and require more expensive
treatment, some of which are required for a lifetime. This is agreeable with a previous study by
Pandor et al 2004. [19] in the UK which found that there was no difference in treatment costs
between the early diagnosis group and late diagnosis group for GA type I. This could be
because the nature of the disease is extremely severe even though it was detected and treated
early. Moreover, the effective treatment for this disease was not yet available. We believe that
unless there is strong evidence, the assumption that early detection can reduce the cost of treat-
ment should not be held.
Thirdly, there were huge differences in the outcome measurement, particularly the life-
years gained between the early diagnosis and late diagnosis group. In a study by Schoen et al
2002 [20], the assumption of life-years gained of 20 years is added into the early detection
group [20]. In an Australian study, it is assumed that patients who lived until 4 years of age
could live up to the age of 66.2 [18]. Accordingly, those values used might be key factors which
supported the favour of screening. However, a more conservative option was applied in a Cana-
dian study where clinical data and the assumption about life expectancy were both used in the
analysis [15]. In this case, it found that the average life-year gained was about 11 years (ranging
from 4–25 years). In our analysis, using Markov modelling to follow the patients for lifetime
estimated that having a screening programme will yield an average life-year gained of 13 years
(ranging 4–40 years without outcome discounting). In particular, if the life expectancy gained
by PKU patients was excluded, the average life-year gained for the rest of the IEM patients was
only 8 years. We believe that from the scarcity of evidence, a conservative assumption for life
expectancy should be the better option to apply to the model.
Lastly, the patient’s quality of life is one of most sensitive parameters to the result. The
higher the quality of life achieved by patients diagnosed early, the more favourable screening
became. From reviewing previous studies, we found that a relatively high value of health utility
weight was applied to the studies which concluded that interventions were cost-effective. The
utility weight of asymptomatic patients of 0.90 is used in the models by Feuchtbaum et al 2006
[16] as well as Tiwana et al 2012 [22], and 0.92 is used in the model by Autti-Roma et al 2005
[56] conducted in California and Texas in the US and Finland, respectively. It is important to
note that those data were obtained from expert opinion [22, 56] or even research assumption
[16] without reporting or mentioning the method of eliciting the utility weight of the patients.
In our study, a more systematic approach was used for an analysis even though we had a small
number of patients and most of them had mental retardation which resulted in difficulties in
trying to extract utility weight data. As suggested by the Thai guidelines for conduction eco-
nomic evaluations [59], the utility data was elicited by a proxy which is the group of people
with knowledge of the diseases through the application of Indirectly measured utility methods
(EQ-5D). This systematic tool for collecting the data was unique in that it can reduce the bias
of the value of quality of life used [60, 61]. From the expert panel, we found that the utility of
asymptomatic patients ranged from 0.49–0.84 for the six selected diseases (mostly under 0.71,
only MCD was higher at 0.84). Obviously, the health utility weight applied for our analysis is
lower than those of other studies which might plausibly result in the unfavourable outcome of
the new intervention.
To argue about whether or not the number of diseases added into the analysis affected the
results of study, we primarily believe that due to the variation of diseases, particularly in the
incidence, level of severity, effective treatment, and costs of treatment, an individual assessment
of the diseases is needed. The theory that including more diseases into the analysis would lead
to favourable results really depends on whether the incremental benefit of the added diseases is
above its incremental cost. If not, the added diseases can create a burden of costs for the whole
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screening programme. Thus, it can be concluded that it is not necessary to include all of the
diseases into the model but instead give priority to evidence-based prioritised diseases and
more attention to the details of each individual disease such as the effectiveness of treatment
and relevant costs. The studies in Wisconsin [17] and the UK [19] proved that even screening
for one or two diseases instead of a combination of 30 diseases may provide for a cost-effective
intervention. In the same way, it does not mean that if the analysis indicates one or more of the
diseases are economical for screening, another can be added to the programme and still be jus-
tified as cost-effective for the reason that there is no additional cost for screening. This is
because the variable costs that come attached to expensive treatments can distort the results of
study. By holding an expert panel, we believe that we have included the most significant dis-
eases into the analysis, and that adding more diseases will not result in a more economical
result unless there is new evidence such as high incidence of the diseases and effectiveness of
treatment.
This study showed a zero utility weight (the equivalent of death) in three groups of patients
including IVA, MSUD with neurological complications, PA with neurological and cardiomy-
opathy complications. This result is in line with a previous study which showed that Thai
patients with a mental retardation combined with a complication, have a very low health utility
that is close to zero [62]. For the three groups of patients, the zero utility can occur because the
diseases are extremely severe. It is also important to address that apart from the main compli-
cations used as health states in the model, patients can also have other complications. In addi-
tion, combining these factors with the algorithm of the Thai EQ-5D could also explain the low
score of patients. The observational study estimated a tariff-a coefficient that was used to sub-
tract full health utility weight (1.00). It was found that in Thailand the tariff is high compared
to other countries (i.e. UK and Japan) [63, 64]. For example, a tariff of constant term is valued
-0.202 in Thailand and -0.081 in the UK. As for the utility score for state 33222, the calculated
utility weight is -0.039 in Thailand compared with 0.161 in the UK.
The budget impact analysis points out that if the screening programme is implemented, the
national healthcare payer must prepare a budget of at least 200 million THB each year. That
amount can be considered substantial because it is comparable to almost one-tenth of the total
healthcare budget allocated to all current screening activities financed by public sources in
Thailand [65]. Therefore, implementing this screening seems to be very challenging under the
rationale of affordability, a core concept of budget impact analysis. Another important point is
that while the annual expenses of screening does not change much each year—thereby reflect-
ing the relatively stable trend of population growth in Thailand—the treatment expenses is
expected to rise sharply and will comprise a significant part of the entire budget in the future.
This reveals that there are higher numbers of cumulative patients each year, each of which
require lifelong treatment. This can be a crucial message delivered to policy makers when con-
sidering all aspects of providing the programme.
There are some limitations regarding the availability of data used in the model. Firstly, most
of the incidences adopted in the analysis were foreign data of Asian countries. Nevertheless,
the studies [6–8] indicated a similarity between uncommon IEM in Asia. So based on our cur-
rent knowledge, the incidence should not be much different as Thailand is comparable with
those countries in terms of ethnicity.
Secondly, although this study had advantages in using actual patient data to estimate the
baseline clinical data, the information on the health outcomes of early-diagnosed patients still
rely on unsubstantial evidence. Without existing well-established studies to observe the poten-
tial benefits of MS/MS screening for IEM, this study had to use information from observational
studies that consisted of a small number of cases as well as expert opinion. However, we believe
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that we performed an extensive search in order to seek for the most credible evidence and used
very conservative assumptions where information was limited.
Thirdly, the estimated cost of the screening programme did not include the cost of setting
up a new screening unit to perform IEM screening and confirmation, transportation, and other
logistics costs. Other potential expenses were also not included, example, human resources
training such as the training of IEM specialists and related paramedics/metabolic dieticians/
metabolic nurses. Nevertheless, we believe that if a new screening programme was provided, it
is likely to be a part of the existing newborn screening institute in Thailand. Thus, it might not
require lots of resource to set up a new centre for the screening programme.
Fourthly, the health utility weight was elicited from expert opinion. There were also many
challenging issues about using QALY measurements in infants and children [66–68]. Never-
theless, given the lack of incidence and extreme difficulties of eliciting health from babies or
patients with mental retardation, we believe that using an expert panel is a viable substitution.
Lastly, while there are several methods to measure health-related quality of life, based on the
pros and cons of each method, the EQ-5D was selected as the most appropriate method for
eliciting quality of life for economic evaluation by the Thai guidelines and this lead to the estab-
lishment of the national EQ-5D tariffs [69]. However, there are issues that needs to be
addressed when using the EQ-5D, especially when it is used to estimate the utility of IEM
patients. There are concerns for the generic health utility measures, for instance, the EQ-5D
may not be sufficiently sensitive for people with mental health problems [70]. It is also possible
that the EQ-5D does not assess some key health-related quality of life domains such as peer
relations or family functioning [60]. In addition, as specific health problems of a certain disease
may not be captured, it is possible to overestimate the utility weight which can potentially ham-
per the estimation of the incremental QALYs especially if the differences in effectiveness
between comparators are marginal [70].
Conclusions
In conclusion, the results of the study indicate that screening for inborn errors of metabolism
in Thailand using MS/MS is economically unattractive given the threshold of cost-effectiveness
in Thailand. Continuing the current screening programme as well as prioritising treatment for
MCD, PKU, MSUD, and IVA patients diagnosed early is the appropriate action to take in
order to deal with IEM. The budget impact analysis suggests that implementing the screening
programme will incur considerable expenses. In addition, a nation-wide epidemiological study
on the incidence of IEM in Thailand was strongly recommended to understand more about the
magnitude of the diseases. Thus, we recommend that Thailand should perform a large-scale
pilot study for an IEM screening programme as a further study.
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